Unidad de Investigación Clínica en Inmunoterapia del Cáncer CNIO-HMarBCN

Luis Álvarez-Vallina Jefe de Unidad de Investigación Clínica
T +34 000002950 (Ext 2950)
lalvarezv@ext.cnio.es

Becarios Post-doctorales

Patricia Almendro
Patricia Hernández
Héctor Fernando Peláez
Daniel Salas
Laura Sanz
Antonio Tapia

Becarios Pre-Doctorales

María Elena Barba
Jaime Franco
Marina Gómez
Susana Luengo
Gonzalo Raso
Lucía Rivas
Miriam Velasco

Técnicos de Laboratorio

María de la Yedra Pacheco

The Cancer Immunotherapy Clinical Research Unit investigates how tumour cells evade immune destruction and develops strategies to re-engage the immune system. Our research spans four complementary areas: (i) boosting endogenous tumour-specific T cell immunity through multispecific antibodies and innovative RNA delivery platforms; (ii) engineering ‘artificial’ tumour-reactive T cells using bispecific T cell engagers (TCEs) and/or membrane-anchored chimeric antigen receptors (CAR); (iii) designing multitargeted tools to detect extracellular and intracellular tumour antigens; and (iv) advancing personalised cancer therapies to the clinic. Our overarching goal is to create next-generation immunotherapies that synergistically activate distinct components of the patient’s immune system against cancer.

Publicaciones recientes

Zagorac I, Ramírez-Fernández Á, Tapia-Galisteo A, Rubio-Pérez L, Gómez-Rosel M, Grau M, Rodríguez-Peralto JL, Álvarez-Vallina L, Blanco B. (2026). mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors. Front Inmmunol (in press). Publicación CNIO.
Falgàs A, Lázaro-Gorines R, Zanetti SR, Rubio-Pérez L, Martinez-Moreno A, Vinyoles M, Guerrero-Murillo M, Fernandez-Fuentes N, Roca-Ho H, Tirado N, Panisello C, Velasco-Hernandez T, Mayado A, Pérez-Pons A, Genesca E, Ribera JM, Ribera J, Camos M, Ramírez-Orellana M, Anguita E, Ballerini P, Fuster JL, Juan M, González-Navarro EAA, Locatelli F, Stam RWW, Querol S, Velasco P, Ortiz-Maldonado V, Martínez-Cibrian N, Delgado J, Orfao A, Alvarez-Vallina L, Bueno C, Menendez P (2025). A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.. Blood 145, 2599-2613. Publicación CNIO.
Battistini E, Lapuhs P, Jiménez A, Garrido-Areal S, Rivas-Gómez L, Zagorac I, Álvarez-Vallina L, Alonso MJ, Sanjurjo L. (2025). Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy. Mol Can 24, 292. Publicación CNIO.
Arroyo-Ródenas J, Falgas A, Díez-Alonso L, Martinez-Moreno A, Roca-Ho H, Gil-Etayo FJ, Pérez-Pons A, Aguilar-Sopeña Ó, Velasco-Sidro M, Gómez-Rosel M, Jiménez-Matías B, Muñoz-Sánchez G, Pacheco Y, Bravo-Martín C, Ramírez-Fernández Á, Jiménez-Reinoso A, González-Navarro EA, Juan M, Orfao A, Blanco B, Roda-Navarro P, Bueno C, Menéndez P, Álvarez-Vallina L. (2025). CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression. J Immunother Cancer 13, e009048. Publicación CNIO.
Gómez-Rosel M, Rubio-Pérez L, Zagorac I, Domínguez-Alonso C, Díez-Alonso L, Hangiu O, Navarro R, Torres-Ruíz R, Rodríguez-Perales S, Blanco FJ, Compte M, Álvarez-Vallina L, Blanco B (2025). Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager. Oncoimmunology 14, 2570224. Publicación CNIO.
Velasco-Sidro M, Arroyo-Ródenas J, Díez-Alonso L, Ramírez-Fernández Á, Álvarez-Vallina L. (2025). Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers. Oncoimmunology 14, 2444701. Publicación CNIO.
Hangiu O, Navarro R, Frago S, Rubio-Pérez L, Tapia-Galisteo A, Díez-Alonso L, Gómez-Rosel M, Silva-Pilipich N, Vanrell L, Smerdou C, Howard KA, Sanz L, Álvarez-Vallina L, Compte M. (2025). Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation. Front Inmmunol 15, 1494206. Publicación CNIO.
Pilati D, Agyei EK, Elkhashab M, Fuchs E, Nielsen IH, Bjerg TW, Anthi AK, Jiménez-Reinoso A, Iversen MB, Pohl L, Narita R, Frago S, Jakobsen MR, Andersen JT, Degn SE, Paludan SR, Alvarez-Vallina L, Howard KA. (2025). Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. J Biol Chem 301, 108508. Publicación CNIO.
Salas-Lloret D, González-Prieto R. (2025). SUMO-Activated Target Traps (SATTs) for the Identification of Specific SUMOylated Proteins for an E3 Ligase of Interest. Methods Mol Biol 2957, 127-140. Publicación CNIO.
Díez-Alonso L, Falgas A, Arroyo-Ródenas J, Romencín PA, Martínez A, Gómez-Rosel M, Blanco B, Jiménez-Reinoso A, Mayado A, Pérez-Pons A, Aguilar-Sopeña Ó, Ramírez-Fernández Á, Segura-Tudela A, Perez-Amill L, Tapia-Galisteo A, Domínguez-Alonso C, Rubio-Pérez L, Jara M, Solé F, Hangiu O, Almagro L, Albitre Á, Penela P, Sanz L, Anguita E, Valeri A, García-Ortiz A, Río P, Juan M, Martínez-López J, Roda-Navarro P, Martín-Antonio B, Orfao A, Menéndez P, Bueno C, Álvarez-Vallina L. (2024). Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. Sci Transl Med 16, adg7962. Publicación CNIO. Open Access
Jiménez-Reinoso A, Molero-Abraham M, Cirauqui C, Blanco B, Garrido-Martin EM, Nehme-Álvarez D, Domínguez-Alonso C, Ramírez-Fernández Á, Díez-Alonso L, Nuñez-Buiza Á, González-Murillo Á, Tobes R, Pareja E, Ramírez-Orellana M, Rodriguez-Peralto JL, Ferrer I, Zugazagoitia J, Paz-Ares L, Álvarez-Vallina L. (2024). CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts.. Oncoimmunology 13, 2392897. Publicación CNIO.
Tapia-Galisteo A, Sánchez-Rodríguez I, Narbona J, Iglesias-Hernández P, Aragón-García S, Jiménez-Reinoso A, Compte M, Khan S, Tsuda T, Chames P, Lacadena J, Álvarez-Vallina L, Sanz L. (2024). Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses. Oncoimmunology 13, 2338558. Publicación CNIO.
Navarro R, Frago S, Hangiu O, Erce-Llamazares A, Lázaro-Gorines R, Morcillo MA, Rodriguez-Peralto JL, Sanz L, Compte M, Alvarez-Vallina L. (2024). Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates. Toxicol Appl Pharm 487, 116961. Publicación CNIO.
Rubio-Pérez L, Frago S, Compte M, Navarro R, Harwood SL, Lázaro-Gorines R, Gómez-Rosel M, Hangiu O, Silva-Pilipich N, Vanrell L, Smerdou C, Álvarez-Vallina L (2024). Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity. Antibodies 13, 34. Publicación CNIO.
Tapia-Galisteo A, Compte M, Álvarez-Vallina L, Sanz L. (2023). When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.. Theranostics 13, 1028-1041. Publicación CNIO.
Tapia-Galisteo A, Álvarez-Vallina L, Sanz L (2023). Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 16, 83. Publicación CNIO.
Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L (2023). A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.. Oncoimmunology 12, 2205336. Publicación CNIO.
Lázaro-Gorines R, Pérez P, Heras-Murillo I, Adán-Barrientos I, Albericio G, Astorgano D, Flores S, Luczkowiak J, Labiod N, Harwood SL, Segura-Tudela A, Rubio-Pérez L, Nugraha Y, Shang X, Li Y, Alfonso C, Adipietro KA, Abeyawardhane DL, Navarro R, Compte M, Yu W, MacKerell AD Jr, Sanz L, Weber DJ, Blanco FJ, Esteban M, Pozharski E, Godoy-Ruiz R, Muñoz IG, Delgado R, Sancho D, García-Arriaza J, Álvarez-Vallina L. (2023). Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.. Adv Sci 10, e2304818. Publicación CNIO.
Blanco B, Ramírez-Fernández A, Bueno C, Argemí-Muntadas A, Fuentes P, Aguilar-Sopeña O, Gutierrez-Agüera F, Romina Zanetti S, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte C, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L (2022). Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T cell engagers.. Cancer Immunol Res 10, 498-511. Publicación en otras instituciones.
Jiménez-Reinoso A, Tirado N, Martinez-Moreno A, Diaz VM, García-Peydró M, Hangiu O, Diez-Alonso L, Albitre A, Penela P, Toribio ML, Menendez P, Alvarez-Vallina L, Sanchez Martinez D. (2022). Efficient treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.. J Immunother Cancer 10, e005333. Publicación CNIO. Open Access
Ramírez-Fernández A, Aguilar-Sopeña O, Díez-Alonso L, Segura-Tudela A, Domínguez-Alonso C, Álvarez-Vallina L, Blanco B (2022). Synapse topology and downmodulation events are determinant for the functional outcome of anti-CD19 T cell-redirecting strategies.. Oncoimmunology 11, 2054106. Publicación en otras instituciones.
Tapia-Galisteo A, Sánchez-Rodríguez I, Aguilar-Sopeña O, Harwood SL, Navarro R, Martín-García L, Gutiérrez F, Corbacho C, Compte M, Blanco FJ, Chames P, Roda-Navarro P, Álvarez-Vallina L, Sanz L (2022). Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. Oncoimmunology 11, 2034355. Publicación en otras instituciones.
Rousso-Noori L, Mastandrea I, Talmor S, Waks T, Globerson Levin A, Haugas M, Teesalu T, Alvarez-Vallina L, Eshhar Z, Friedmann-Morvinski D (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.. Nat Commun 12, 3615. Publicación en otras instituciones. Open Access
Blanco B, Domínguez-Alonso C, Alvarez-Vallina L. (2021). Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.. Clin Cancer Res 27, 5457-5464. Publicación en otras instituciones.
Compte M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, Romero E, Ferrer I, Garrido-Martin EM, Enguita AB, Ochoa MC, Blanco B, Oteo M, Merino N, Nehme-Álvarez D, Hangiu O, Domínguez-Alonso C, Zonca M, Ramírez-Fernández A, Blanco FJ, Morcillo MA, Muñoz IG, Melero I, Rodriguez-Peralto JL, Paz-Ares L, Sanz L, Alvarez-Vallina L. (2021). An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. Clin Cancer Res 27, 3167-3177. Publicación CNIO.
Jiménez-Reinoso A, Nehme-Álvarez D, Domínguez-Alonso C, Álvarez-Vallina L. (2021). Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential.. Front Oncol 10, 593848. Publicación en otras instituciones.
Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. (2021). Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun Biol 4, 310. Publicación en otras instituciones.